West Pharmaceutical Services, Inc. (WST) is a publicly traded Healthcare sector company. As of May 20, 2026, WST trades at $308.45 with a market cap of $21.51B and a P/E ratio of 40.45. WST moved +0.46% today. Year to date, WST is +9.49%; over the trailing twelve months it is +41.81%. Its 52-week range spans $187.43 to $352.33. Analyst consensus is buy with an average price target of $347.50. Rallies surfaces WST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
West Pharmaceutical (WST) climbs as raised 2026 guidance sustains post-earnings bid: West Pharmaceutical Services shares are higher as investors continue to react to the company’s April 23, 2026 Q1 beat and raised full-year 2026 outlook. West lifted 2026 net sales guidance to $3.295B–$3.350B and adjusted EPS guidance to $8.40–$8.75, reinforcing momentum in high-value components.
| Metric | Value |
|---|---|
| Price | $308.45 |
| Market Cap | $21.51B |
| P/E Ratio | 40.45 |
| EPS | $7.52 |
| Dividend Yield | 0.22% |
| 52-Week High | $352.33 |
| 52-Week Low | $187.43 |
| Volume | 403.36K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.22B |
| Net Income | $542.70M |
| Gross Margin | 36.28% |
7 analysts cover WST: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $347.50.